Reporting on San Antonio’s Startups

From companies commercializing a cancer prevention drug and urological medical device, to reintroducing transfusion methods and working on a new vaccine and chromosomal abnormalities research, the Health Cell’s annual State of the Industry 2018 event Feb. 6 highlighted San Antonio’s thriving bioscience sector.“This is our fourth annual event,” Health Cell co-founder Beth Eby said. "We aim for a good representation of those ‘who knew?’ stories from San Antonio’s bioscience and healthcare sector."The five stories reflect how innovators in San Antonio are significantly advancing the understanding of critical issues in the life sciences, having a substantial impact on public health, or highlighting pressing health care issues.New Cancer Prevention Drug Boosts Body’s Immune System ...

San Antonio-based Rapamycin Holdings, Inc. (RHI) is bringing a ground-breaking cancer prevention drug to market. The drug company is commercializing eRapa, a novel, proprietary reformulation of the generic drug Rapamycin.Hailed as the 2009 scientific “Breakthrough of the Year” by Science magazine, eRapa is the first drug proven to extend life span in mammals, on average by 20 percent. The July 2009 issue of Nature reported that eRapa boosts health and longevity in mice, the first time any drug has extended a mammal’s life span.Rapamycin is an antibiotic derived from microbes discovered in the soils of Easter Island in 1972 and was approved by the Food and Drug Administration (FDA) in 1999 as an immunosuppressant. It has long been used by transplant patients to help fight organ rej...

Articles

Five Stories From San Antonio’s Thriving Bioscience Industry

Rapamycin Holdings, Inc.